vs

Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

ADC Therapeutics SA is the larger business by last-quarter revenue ($23.1M vs $21.8M, roughly 1.1× NEKTAR THERAPEUTICS). On growth, ADC Therapeutics SA posted the faster year-over-year revenue change (36.4% vs -25.3%). Over the past eight quarters, ADC Therapeutics SA's revenue compounded faster (13.7% CAGR vs 0.4%).

ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

ADCT vs NKTR — Head-to-Head

Bigger by revenue
ADCT
ADCT
1.1× larger
ADCT
$23.1M
$21.8M
NKTR
Growing faster (revenue YoY)
ADCT
ADCT
+61.6% gap
ADCT
36.4%
-25.3%
NKTR
Faster 2-yr revenue CAGR
ADCT
ADCT
Annualised
ADCT
13.7%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ADCT
ADCT
NKTR
NKTR
Revenue
$23.1M
$21.8M
Net Profit
$-36.1M
Gross Margin
Operating Margin
-77.7%
-126.9%
Net Margin
-165.4%
Revenue YoY
36.4%
-25.3%
Net Profit YoY
-596.9%
EPS (diluted)
$0.04
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADCT
ADCT
NKTR
NKTR
Q4 25
$23.1M
$21.8M
Q3 25
$15.8M
$11.8M
Q2 25
$18.1M
$11.2M
Q1 25
$17.4M
$10.5M
Q4 24
$16.9M
$29.2M
Q3 24
$18.0M
$24.1M
Q2 24
$17.0M
$23.5M
Q1 24
$17.8M
$21.6M
Net Profit
ADCT
ADCT
NKTR
NKTR
Q4 25
$-36.1M
Q3 25
$-41.0M
$-35.5M
Q2 25
$-56.6M
$-41.6M
Q1 25
$-38.6M
$-50.9M
Q4 24
$7.3M
Q3 24
$-44.0M
$-37.1M
Q2 24
$-36.5M
$-52.4M
Q1 24
$-46.6M
$-36.8M
Gross Margin
ADCT
ADCT
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
ADCT
ADCT
NKTR
NKTR
Q4 25
-77.7%
-126.9%
Q3 25
-196.6%
-268.6%
Q2 25
-244.1%
-324.2%
Q1 25
-163.5%
-425.8%
Q4 24
-191.8%
49.2%
Q3 24
-197.4%
-142.4%
Q2 24
-170.5%
-211.9%
Q1 24
-188.3%
-163.7%
Net Margin
ADCT
ADCT
NKTR
NKTR
Q4 25
-165.4%
Q3 25
-260.1%
-301.3%
Q2 25
-313.2%
-372.2%
Q1 25
-221.8%
-486.4%
Q4 24
24.9%
Q3 24
-244.1%
-153.6%
Q2 24
-214.6%
-222.9%
Q1 24
-261.1%
-170.1%
EPS (diluted)
ADCT
ADCT
NKTR
NKTR
Q4 25
$0.04
$-4.67
Q3 25
$-0.30
$-1.87
Q2 25
$-0.50
$-2.95
Q1 25
$-0.36
$-0.24
Q4 24
$-0.26
$-2.07
Q3 24
$-0.42
$-2.66
Q2 24
$-0.38
$-3.76
Q1 24
$-0.56
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADCT
ADCT
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$261.3M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-185.8M
$89.8M
Total Assets
$323.1M
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADCT
ADCT
NKTR
NKTR
Q4 25
$261.3M
$15.1M
Q3 25
$234.7M
$41.0M
Q2 25
$264.6M
$43.0M
Q1 25
$194.7M
$38.9M
Q4 24
$250.9M
$44.3M
Q3 24
$274.3M
$30.1M
Q2 24
$300.1M
$27.9M
Q1 24
$234.3M
$48.6M
Stockholders' Equity
ADCT
ADCT
NKTR
NKTR
Q4 25
$-185.8M
$89.8M
Q3 25
$-238.2M
$85.1M
Q2 25
$-199.2M
$-24.2M
Q1 25
$-238.2M
$13.7M
Q4 24
$-202.6M
$60.7M
Q3 24
$-171.9M
$48.9M
Q2 24
$-131.7M
$79.7M
Q1 24
$-194.4M
$126.7M
Total Assets
ADCT
ADCT
NKTR
NKTR
Q4 25
$323.1M
$280.4M
Q3 25
$289.8M
$301.3M
Q2 25
$321.6M
$207.5M
Q1 25
$272.5M
$256.2M
Q4 24
$322.0M
$303.9M
Q3 24
$349.1M
$308.0M
Q2 24
$371.8M
$343.3M
Q1 24
$308.0M
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADCT
ADCT
NKTR
NKTR
Operating Cash FlowLast quarter
$-31.1M
$-65.0M
Free Cash FlowOCF − Capex
$-65.0M
FCF MarginFCF / Revenue
-298.0%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADCT
ADCT
NKTR
NKTR
Q4 25
$-31.1M
$-65.0M
Q3 25
$-29.6M
$-48.8M
Q2 25
$-24.1M
$-45.7M
Q1 25
$-56.3M
$-49.1M
Q4 24
$-21.9M
$-46.2M
Q3 24
$-25.0M
$-43.9M
Q2 24
$-32.8M
$-37.7M
Q1 24
$-44.1M
$-47.9M
Free Cash Flow
ADCT
ADCT
NKTR
NKTR
Q4 25
$-65.0M
Q3 25
$-48.9M
Q2 25
$-45.8M
Q1 25
$-56.6M
$-49.1M
Q4 24
$-21.9M
$-46.6M
Q3 24
$-25.3M
$-44.6M
Q2 24
$-32.9M
$-37.9M
Q1 24
$-44.6M
$-48.0M
FCF Margin
ADCT
ADCT
NKTR
NKTR
Q4 25
-298.0%
Q3 25
-414.5%
Q2 25
-409.6%
Q1 25
-325.2%
-469.0%
Q4 24
-129.8%
-159.9%
Q3 24
-140.2%
-184.9%
Q2 24
-193.0%
-161.3%
Q1 24
-250.0%
-222.0%
Capex Intensity
ADCT
ADCT
NKTR
NKTR
Q4 25
0.0%
0.1%
Q3 25
0.0%
1.0%
Q2 25
0.0%
0.3%
Q1 25
1.5%
0.0%
Q4 24
0.5%
1.6%
Q3 24
1.2%
2.8%
Q2 24
0.2%
0.8%
Q1 24
3.0%
0.7%
Cash Conversion
ADCT
ADCT
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-6.36×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons